Menu Search
Equities

Nightingale Health Oyj

7XE:FRA

Nightingale Health Oyj

Actions
  • Price (EUR)2.78
  • Today's Change-0.13 / -4.47%
  • Shares traded28.00
  • 1 Year change+142.58%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nightingale Health Oyj is a Finland-based health technology company that aims to promote preventative health and help people stay healthy. The blood analysis technology developed by Nightingale measures a broad group of biomarkers from a single blood sample, recognizing individual disease risks. The Company provides people with comprehensive insights on health, helps them make better decisions regarding their health and connects them with healthcare experts that offer preventative services for maintaining health. Nightingale Health Oy is the Parent Company in the Nightingale Group. The Group comprises the parent Company’s subsidiaries: Nightingale Health United States Inc, Nightingale Health Asia Pte Ltd, Nightingale Health Japan KK as well as NG Health Sweden AB. The Company owns and independently oversees two laboratories in Finland, in Helsinki and Kuopio, and one laboratory in Tokyo, Japan.

  • Revenue in EUR (TTM)4.36m
  • Net income in EUR-17.46m
  • Incorporated2002
  • Employees86.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		HEALTH:HEX since
announced		Transaction
value
Welltus IncAnnounced07 Mar 202407 Mar 2024Announced157.94%--
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.